Skip to content

The role of Copeptin as a biomarker of volume status in pediatric polyuric tubulopathies

The role of Copeptin as a biomarker of volume status in pediatric polyuric tubulopathies - Copeptin study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON57173
Enrollment
10
Registered
2024-10-21
Start date
2025-01-08
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

renal disease tubulopathy nierziekte

Interventions

Niet van toepassing

Sponsors

Cruces University Hospital
Lead Sponsor

Eligibility

Age
2 Years to 17 Years

Inclusion criteria

Inclusion criteria: • Child = 60 ml/min/1.73 m2 (for patients older than 1 year).

Exclusion criteria

Exclusion criteria: • Advanced chronic kidney disease (CKD 3-5).

Design outcomes

Primary

MeasureTime frame
- To investigate copeptin levels in pediatric polyuric tubulopathies such as Nephrogenic Diabetes Insipidus (NDI), Renal Fanconi syndrome and Bartter syndrome to use it as biomarker for the volume state of these patients.

Secondary

MeasureTime frame
- Assess the relation between copeptin levels and other parameters of kidney function and water and salt homeostasis. In particular: o eGFR; o Serum electrolytes and acid base status; o urine and plasma osmolality; o urinary excretion of AQP2; o urinary levels of cAMP; o urinary levels of cAMP;o urine ammonium-pH indexo plasma renin and aldosterone levels; o rate of growth.

Countries

Belgium, Macedonia, Netherlands, Spain, Turkey

Contacts

Public ContactM.T.P. Besouw

Universitair Medisch Centrum Groningen

kindernefrologie@umcg.nl0503612486

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Aug 9, 2026